GEN EdgeVol. 6, No. 1 TopicsJPM 2024: Veracyte's C2i Genomics Acquisition Adds AI Readouts to Liquid Biopsy TestingC2i Genomics' whole-genome, AI-powered approach generates broad signatures from blood more quickly and efficiently than bespoke panelsJonathan D GrinsteinJonathan D GrinsteinSearch for more papers by this authorPublished Online:8 Jan 2024https://doi.org/10.1089/genedge.6.01.005AboutSectionsView articleView Full TextPDF/EPUB Permissions & CitationsPermissionsDownload CitationsTrack CitationsAdd to favorites Back To Publication ShareShare onFacebookXLinked InRedditEmail View articleFiguresReferencesRelatedDetails Volume 6Issue 1Jan 2024 Information© 2024 by GEN PublishingTo cite this article:Jonathan D Grinstein.JPM 2024: Veracyte's C2i Genomics Acquisition Adds AI Readouts to Liquid Biopsy Testing.GEN Edge.Jan 2024.19-21.http://doi.org/10.1089/genedge.6.01.005Published in Volume: 6 Issue 1: January 8, 2024PDF download

GEN EdgeVol. 5, No. 1 Artificial IntelligenceBiotech Leaders Discuss Therapeutic Breakthroughs at the WuXi AppTec Global ForumNext door to the J.P. Morgan 2023 Healthcare Conference, an all-star panel featuring Todd Golub, John Ngai, Vijay Pande, Aviv Regev and Michael Severino examined the state of innovationJonathan D GrinsteinJonathan D GrinsteinSearch for more papers by this authorPublished Online:11 Jan 2023https://doi.org/10.1089/genedge.5.1.10AboutSectionsView articleView Full TextPDF/EPUB Permissions & CitationsPermissionsDownload CitationsTrack CitationsAdd to favorites Back To Publication ShareShare onFacebookTwitterLinked InRedditEmail View articleFiguresReferencesRelatedDetails Volume 5Issue 1Jan 2023 Information© 2023 by GEN PublishingTo cite this article:Jonathan D Grinstein.Biotech Leaders Discuss Therapeutic Breakthroughs at the WuXi AppTec Global Forum.GEN Edge.Jan 2023.39-41.http://doi.org/10.1089/genedge.5.1.10Published in Volume: 5 Issue 1: January 11, 2023PDF download

GEN EdgeVol. 5, No. 1 TopicsPrecede Biosciences Launches with Cell-Free Genomic Diagnostic for Drug Development and Precision MedicineLed by CEO Rehan Verjee, the Boston-based company emerges from stealth behind a genome-wide platform that profiles circulating chromatin and the DNA methylome to deliver resolution into the dynamic activation of genes and pathways in diseased tissuesJonathan D. GrinsteinJonathan D. GrinsteinSearch for more papers by this authorPublished Online:5 Oct 2023https://doi.org/10.1089/genedge.5.1.131AboutSectionsView articleView Full TextPDF/EPUB Permissions & CitationsPermissionsDownload CitationsTrack CitationsAdd to favorites Back To Publication ShareShare onFacebookTwitterLinked InRedditEmail View articleFiguresReferencesRelatedDetails Volume 5Issue 1Jan 2023 Information© 2023 by GEN PublishingTo cite this article:Jonathan D. Grinstein.Precede Biosciences Launches with Cell-Free Genomic Diagnostic for Drug Development and Precision Medicine.GEN Edge.Jan 2023.679-682.http://doi.org/10.1089/genedge.5.1.131Published in Volume: 5 Issue 1: October 5, 2023PDF download

GEN EdgeVol. 5, No. 1 GEN EdgeReporter's Notebook: Opening Day at the J.P. Morgan Healthcare ConferenceAfter going virtual for the past two years, the 41st J.P. Morgan Healthcare Conference returned to the streets of San Francisco, filling hotel lobbies and conference rooms with overdue salutations and conversations as the industry seeks to turn its fortunes aroundJonathan D GrinsteinJonathan D GrinsteinSearch for more papers by this authorPublished Online:10 Jan 2023https://doi.org/10.1089/genedge.5.1.08AboutSectionsView articleView Full TextPDF/EPUB Permissions & CitationsPermissionsDownload CitationsTrack CitationsAdd to favorites Back To Publication ShareShare onFacebookTwitterLinked InRedditEmail View articleFiguresReferencesRelatedDetails Volume 5Issue 1Jan 2023 Information© 2023 by GEN PublishingTo cite this article:Jonathan D Grinstein.Reporter's Notebook: Opening Day at the J.P. Morgan Healthcare Conference.GEN Edge.Jan 2023.33-35.http://doi.org/10.1089/genedge.5.1.08Published in Volume: 5 Issue 1: January 10, 2023PDF download

GEN EdgeVol. 5, No. 1 TopicsMeeting on the Mesa: Without Ethics, Cell and Gene Therapy Will FailIn a field that is poised to do great good in domains where human beings have basically been incapable of responding to human needs, it requires thinking deliberately and carefully about what doing good meansJonathan D. GrinsteinJonathan D. GrinsteinSearch for more papers by this authorPublished Online:13 Oct 2023https://doi.org/10.1089/genedge.5.1.138AboutSectionsView articleView Full TextPDF/EPUB Permissions & CitationsPermissionsDownload CitationsTrack CitationsAdd to favorites Back To Publication ShareShare onFacebookTwitterLinked InRedditEmail View articleFiguresReferencesRelatedDetails Volume 5Issue 1Jan 2023 Information© 2023 by GEN PublishingTo cite this article:Jonathan D. Grinstein.Meeting on the Mesa: Without Ethics, Cell and Gene Therapy Will Fail.GEN Edge.Jan 2023.714-718.http://doi.org/10.1089/genedge.5.1.138Published in Volume: 5 Issue 1: October 13, 2023PDF download

GEN EdgeVol. 5, No. 1 GEN EdgeAmped Up: VedaBio Launches with $40+ Million Toward a CRISPR Molecular Detection PlatformCEO Anurup Ganguli said that Cascade technology outperforms nucleic acid detection platforms dependent on target amplification, offering greater speed and accuracyJonathan D. GrinsteinJonathan D. GrinsteinSearch for more papers by this authorPublished Online:17 Oct 2023https://doi.org/10.1089/genedge.5.1.140AboutSectionsView articleView Full TextPDF/EPUB Permissions & CitationsPermissionsDownload CitationsTrack CitationsAdd to favorites Back To Publication ShareShare onFacebookTwitterLinked InRedditEmail View articleFiguresReferencesRelatedDetails Volume 5Issue 1Jan 2023 Information© 2023 by GEN PublishingTo cite this article:Jonathan D. Grinstein.Amped Up: VedaBio Launches with $40+ Million Toward a CRISPR Molecular Detection Platform.GEN Edge.Jan 2023.721-724.http://doi.org/10.1089/genedge.5.1.140Published in Volume: 5 Issue 1: October 17, 2023PDF download

Genetic Engineering & Biotechnology NewsVol. 43, No. 2 DepartmentsMaking Medicines Based on Transplanting Differentiated CellsAfter striking a $670M deal with Roche's Genentech, Lineage Cell Therapeutics aims to improve existing cell therapy programs and start new onesJonathan D. GrinsteinJonathan D. GrinsteinSearch for more papers by this authorPublished Online:10 Feb 2023https://doi.org/10.1089/gen.43.02.07AboutSectionsView articleView Full TextPDF/EPUB Permissions & CitationsPermissionsDownload CitationsTrack CitationsAdd to favorites Back To Publication ShareShare onFacebookTwitterLinked InRedditEmail View articleFiguresReferencesRelatedDetails Volume 43Issue 2Feb 2023 Information© 2023 by GEN PublishingTo cite this article:Jonathan D. Grinstein.Making Medicines Based on Transplanting Differentiated Cells.Genetic Engineering & Biotechnology News.Feb 2023.18-19.http://doi.org/10.1089/gen.43.02.07Published in Volume: 43 Issue 2: February 10, 2023PDF download

GEN EdgeVol. 4, No. 1 GEN EdgeNucleotide Novellas: Tessera Therapeutics Writes Genetic Medicines to Cure DiseasesThe Flagship Pioneering company has operationalized mobile genetic elements to make small and large permanent alterations to the human genomeJonathan D GrinsteinJonathan D GrinsteinSearch for more papers by this authorPublished Online:12 Dec 2022https://doi.org/10.1089/genedge.4.1.157AboutSectionsView articleView Full TextPDF/EPUB Permissions & CitationsPermissionsDownload CitationsTrack CitationsAdd to favorites Back To Publication ShareShare onFacebookTwitterLinked InRedditEmail View articleFiguresReferencesRelatedDetails Volume 4Issue 1Jan 2022 Information© 2022 by GEN PublishingTo cite this article:Jonathan D Grinstein.Nucleotide Novellas: Tessera Therapeutics Writes Genetic Medicines to Cure Diseases.GEN Edge.Jan 2022.931-938.http://doi.org/10.1089/genedge.4.1.157Published in Volume: 4 Issue 1: December 12, 2022PDF download

GEN EdgeVol. 5, No. 1 TopicsThe Immaculate Conception of Gleevec, As Told by Brian DrukerThe Lifetime Achievement Awardee at the 2023 Stanford Drug Discovery Symposium shared his journey from medical school to his seminal work on kinase inhibitors to treat cancerJonathan D GrinsteinJonathan D GrinsteinSearch for more papers by this authorPublished Online:25 Apr 2023https://doi.org/10.1089/genedge.5.1.62AboutSectionsView articleView Full TextPDF/EPUB Permissions & CitationsPermissionsDownload CitationsTrack CitationsAdd to favorites Back To Publication ShareShare onFacebookTwitterLinked InRedditEmail View articleFiguresReferencesRelatedDetails Volume 5Issue 1Jan 2023 Information© 2023 by GEN PublishingTo cite this article:Jonathan D Grinstein.The Immaculate Conception of Gleevec, As Told by Brian Druker.GEN Edge.Jan 2023.325-328.http://doi.org/10.1089/genedge.5.1.62Published in Volume: 5 Issue 1: April 25, 2023PDF download

GEN EdgeVol. 5, No. 1 TopicsBPI News: Primrose Bio Blossoms from Pelican and Primordial Genetics MergerThe cross-pollination of platforms enables the San Diego-based company to create a novel way of enhancing productivity to enable the next generation of biological therapeuticsJonathan D. GrinsteinJonathan D. GrinsteinSearch for more papers by this authorPublished Online:19 Sep 2023https://doi.org/10.1089/genedge.5.1.119AboutSectionsView articleView Full TextPDF/EPUB Permissions & CitationsPermissionsDownload CitationsTrack CitationsAdd to favorites Back To Publication ShareShare onFacebookTwitterLinked InRedditEmail View articleFiguresReferencesRelatedDetails Volume 5Issue 1Jan 2023 Information© 2023 by GEN PublishingTo cite this article:Jonathan D. Grinstein.BPI News: Primrose Bio Blossoms from Pelican and Primordial Genetics Merger.GEN Edge.Jan 2023.616-618.http://doi.org/10.1089/genedge.5.1.119Published in Volume: 5 Issue 1: September 19, 2023PDF download

GEN EdgeVol. 5, No. 1 TopicsMeeting on the Mesa: How to Bring Cell and Gene Therapies to MarketRegulatory approval, manufacturing, and reimbursement payment models for cell and gene therapies take center stage at the 2023 Cell & Gene Meeting on the MesaJonathan D. GrinsteinJonathan D. GrinsteinSearch for more papers by this authorPublished Online:12 Oct 2023https://doi.org/10.1089/genedge.5.1.136AboutSectionsView articleView Full TextPDF/EPUB Permissions & CitationsPermissionsDownload CitationsTrack CitationsAdd to favorites Back To Publication ShareShare onFacebookTwitterLinked InRedditEmail View articleFiguresReferencesRelatedDetails Volume 5Issue 1Jan 2023 Information© 2023 by GEN PublishingTo cite this article:Jonathan D. Grinstein.Meeting on the Mesa: How to Bring Cell and Gene Therapies to Market.GEN Edge.Jan 2023.703-707.http://doi.org/10.1089/genedge.5.1.136Published in Volume: 5 Issue 1: October 12, 2023PDF download

GEN EdgeVol. 5, No. 1 GEN EdgeTo Health: Xalud Therapeutics Is Bringing Gene Therapy to the MassesThe biotechnology company is developing a non-viral DNA-delivered therapy platform to treat conditions caused by pathologic inflammationJonathan D GrinsteinJonathan D GrinsteinSearch for more papers by this authorPublished Online:8 Feb 2023https://doi.org/10.1089/genedge.5.1.33AboutSectionsView articleView Full TextPDF/EPUB Permissions & CitationsPermissionsDownload CitationsTrack CitationsAdd to favorites Back To Publication ShareShare onFacebookTwitterLinked InRedditEmail View articleFiguresReferencesRelatedDetails Volume 5Issue 1Jan 2023 Information© 2023 by GEN PublishingTo cite this article:Jonathan D Grinstein.To Health: Xalud Therapeutics Is Bringing Gene Therapy to the Masses.GEN Edge.Jan 2023.156-161.http://doi.org/10.1089/genedge.5.1.33Published in Volume: 5 Issue 1: February 8, 2023PDF download

GEN EdgeVol. 5, No. 1 Cell TherapyLineage Cell Therapeutics Makes Medicines Based on Transplanting Differentiated CellsAfter striking a deal with Roche's Genentech worth $670 million, the cell therapy company is working to improve its existing cell therapy programs and start new ones.Jonathan D GrinsteinJonathan D GrinsteinSearch for more papers by this authorPublished Online:5 Jan 2023https://doi.org/10.1089/genedge.5.1.03AboutSectionsView articleView Full TextPDF/EPUB Permissions & CitationsPermissionsDownload CitationsTrack CitationsAdd to favorites Back To Publication ShareShare onFacebookTwitterLinked InRedditEmail View articleFiguresReferencesRelatedDetails Volume 5Issue 1Jan 2023 Information© 2023 by GEN PublishingTo cite this article:Jonathan D Grinstein.Lineage Cell Therapeutics Makes Medicines Based on Transplanting Differentiated Cells.GEN Edge.Jan 2023.9-14.http://doi.org/10.1089/genedge.5.1.03Published in Volume: 5 Issue 1: January 5, 2023PDF download

GEN EdgeVol. 5, No. 1 TopicsSpin Me Round: iBio Reemerges as Innovator of Precision Antibody ImmunotherapiesIn transitioning from CDMO and cGMP biologics manufacturing to a AI-powered biotechnology company, iBio has changed leadership and location as part of their mission to become a stalwart in developing antibodies for hard-to-drug targetsJonathan D GrinsteinJonathan D GrinsteinSearch for more papers by this authorPublished Online:27 May 2023https://doi.org/10.1089/genedge.5.1.78AboutSectionsView articleView Full TextPDF/EPUB Permissions & CitationsPermissionsDownload CitationsTrack CitationsAdd to favorites Back To Publication ShareShare onFacebookTwitterLinked InRedditEmail View articleFiguresReferencesRelatedDetails Volume 5Issue 1Jan 2023 Information© 2023 by GEN PublishingTo cite this article:Jonathan D Grinstein.Spin Me Round: iBio Reemerges as Innovator of Precision Antibody Immunotherapies.GEN Edge.Jan 2023.401-405.http://doi.org/10.1089/genedge.5.1.78Published in Volume: 5 Issue 1: May 27, 2023PDF download

GEN EdgeVol. 5, No. 1 Genome EditingArbor and Vertex to Advance Reverse Transcriptase Genetic MedicinesAmidst some opposition, Vertex will receive rights to Arbor's obscure novel precision reverse transcription editing technology to make in vivo gene therapiesJonathan D GrinsteinJonathan D GrinsteinSearch for more papers by this authorPublished Online:17 Jan 2023https://doi.org/10.1089/genedge.5.1.14AboutSectionsView articleView Full TextPDF/EPUB Permissions & CitationsPermissionsDownload CitationsTrack CitationsAdd to favorites Back To Publication ShareShare onFacebookTwitterLinked InRedditEmail View articleFiguresReferencesRelatedDetails Volume 5Issue 1Jan 2023 Information© 2023 by GEN PublishingTo cite this article:Jonathan D Grinstein.Arbor and Vertex to Advance Reverse Transcriptase Genetic Medicines.GEN Edge.Jan 2023.56-60.http://doi.org/10.1089/genedge.5.1.14Published in Volume: 5 Issue 1: January 17, 2023PDF download

GEN EdgeVol. 5, No. 1 TopicASGCT News: Siren Biotechnology Hails Universal Gene Therapy for OncologyNicole Paulk, PhD, emerges from stealth to unveil her Bay area start-up that integrates AAV gene therapy with cytokine immunotherapy to reimagine the elimination of tumor cells and the induction of anti-tumor immunityJonathan D GrinsteinJonathan D GrinsteinSearch for more papers by this authorPublished Online:17 May 2023https://doi.org/10.1089/genedge.5.1.74AboutSectionsView articleView Full TextPDF/EPUB Permissions & CitationsPermissionsDownload CitationsTrack CitationsAdd to favorites Back To Publication ShareShare onFacebookTwitterLinked InRedditEmail View articleFiguresReferencesRelatedDetails Volume 5Issue 1Jan 2023 Information© 2023 by GEN PublishingTo cite this article:Jonathan D Grinstein.ASGCT News: Siren Biotechnology Hails Universal Gene Therapy for Oncology.GEN Edge.Jan 2023.382-386.http://doi.org/10.1089/genedge.5.1.74Published in Volume: 5 Issue 1: May 17, 2023PDF download

GEN EdgeVol. 5, No. 1 TopicsFrom Smudge to Sequence: Quantum-Si Commercializes the First Single-Molecule Protein NGS PlatformThe latest innovation from NGS pioneer Jonathan Rothberg, Platinum™ enables broad-scale access to proteomic data and is immediately available for order.Jonathan D GrinsteinJonathan D GrinsteinSearch for more papers by this authorPublished Online:3 Jan 2023https://doi.org/10.1089/genedge.5.1.01AboutSectionsView articleView Full TextPDF/EPUB Permissions & CitationsPermissionsDownload CitationsTrack CitationsAdd to favorites Back To Publication ShareShare onFacebookTwitterLinked InRedditEmail View articleFiguresReferencesRelatedDetails Volume 5Issue 1Jan 2023 Information© 2023 by GEN PublishingTo cite this article:Jonathan D Grinstein.From Smudge to Sequence: Quantum-Si Commercializes the First Single-Molecule Protein NGS Platform.GEN Edge.Jan 2023.1-4.http://doi.org/10.1089/genedge.5.1.01Published in Volume: 5 Issue 1: January 3, 2023PDF download